Akoya Biosciences, Inc. (AKYA)
| Market Cap | 481.90M |
| Revenue (ttm) | 59.60M |
| Net Income (ttm) | -51.20M |
| Shares Out | 37.59M |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,991 |
| Open | 12.48 |
| Previous Close | 12.57 |
| Day's Range | 12.30 - 12.98 |
| 52-Week Range | 8.02 - 21.84 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 18.62 (+45.2%) |
| Earnings Date | Aug 9, 2022 |
About AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microar... [Read more...]
Financial Performance
In 2021, AKYA's revenue was $54.92 million, an increase of 29.39% compared to the previous year's $42.44 million. Losses were -$42.94 million, 157.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for AKYA stock is "Buy." The 12-month stock price forecast is 18.62, which is an increase of 45.24% from the latest price.
News
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon's Proprietary OncoSign...
The OncoSignature® test developed based on Acrivon's AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted onco...
Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual M...
PhenoCycler™-Fusion will enable single-cell, whole-slide spatial multiomic capabilities on a single platform PhenoCycler™-Fusion will enable single-cell, whole-slide spatial multiomic capabilities on a ...
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
Akoya (AKYA) delivered earnings and revenue surprises of -18.92% and 14.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
Q1 2022 revenue $16.9 million, 38% growth over prior year period Raising FY 2022 revenue guidance range to $70-73 million
Akoya to Participate at Three Upcoming Investor Conferences
MARLBOROUGH, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming inves...
Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer
Dr. El-Gabry's extensive leadership experience will be critical to accelerating Akoya's groundbreaking spatial biomarker research technologies into clinical tools that will impact patient care Dr. El-Ga...
Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022
MARLBOROUGH, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the firs...
New Strong Sell Stocks for April 11th
DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on April 11, 2022.
Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022
MARLBOROUGH, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced that two important milestones on advancing the speed and sca...
New Strong Sell Stocks for April 1st
AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
New Strong Sell Stocks for March 17th
DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2022.
Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook
Q4 2021 revenue $16.2 million and FY 2021 revenue $54.9 million FY 2022 revenue guidance $69 - 71 million
Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annu...
MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourt...
Is a Surprise Coming for Akoya Biosciences (AKYA) This Earnings Season?
Akoya Biosciences (AKYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Akoya Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
MARLBOROUGH, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the BTIG ...
Akoya Biosciences Appoints Marilee Moy as Chief People Officer
Ms. Moy brings 30 years of HR leadership experience at high-performing companies Ms. Moy brings 30 years of HR leadership experience at high-performing companies
Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Fastest Single-Cell Spatial Biology System
Powered by novel technology that can map a million cells in 10 minutes, the system enables unbiased spatial discovery across whole slides, at scale Powered by novel technology that can map a million cel...
Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
MARLBOROUGH, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter...
Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed...
Akoya's powerful new PhenoCycler™-Fusion system combined with Bio-Techne's proven and established RNAScope® technology will enable comprehensive spatial phenotyping of RNA and protein biomarkers Akoya's...
Bio-Techne and Akoya Biosciences Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed...
MINNEAPOLIS and MARLBOROUGH, Mass., Jan. 5, 2022 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinica...
Akoya Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
MARLBOROUGH, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the 40th ...
Akoya Biosciences Unveils Comprehensive Roadmap of Innovations at Inaugural Spatial Day Event
-Company previews an integrated suite of solutions, including the new PhenoCycler ™ -Fusion System for unbiased spatial discovery, at unprecedented speeds
Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Too...
Partnership pairs Akoya's spatial phenotyping solutions and PathAI's AI-based algorithms to elucidate spatial biomarker signatures for biopharma partners Partnership pairs Akoya's spatial phenotyping so...
Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying Its Spatial Biology Technologies to Accele...
Certification ensures Akoya's cutting-edge spatial biology tools meet the highest standards for translational medicine and clinical research, with longer term potential for companion diagnostics.
Akoya Biosciences to Host Inaugural Spatial Day on December 15, 2021
The program will highlight the latest breakthroughs and applications in spatial biology and the company's latest innovations to accelerate breakthroughs in discovery and clinical research.